ArticleCureus2026
Remarkable Response to Etoposide and Cisplatin in Aggressive-Variant Prostate Cancer With Low Prostate-Specific Antigen Levels: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate-specific antigen (PSA) is a cornerstone of screening for prostate cancer (PC); however, serum PSA levels may remain deceptively low in certain high-grade, aggressive subtypes. Aggressive-variant prostate cancer (AVPC) is a clinical entity characterized by rapid progression, bulky lymphadenopathy, and visceral metastases despite low or non-correlative PSA levels, often requiring treatment approaches beyond conventional therapies. Here, we report the case of a 69-year-old Japanese man with multiple comorbidities, including diabetes, hyperlipidemia, hypertension, angina pectoris, and lower limb occlusive arteriosclerosis, who presented to our center with lower back pain and gait disturbance. Diagnostic imaging demonstrated extensive pelvic bone metastases, seminal vesicle invasion, and pelvic and para-aortic lymphadenopathy. Laboratory evaluation showed a normal PSA level of 2.95 ng/mL and an elevated alkaline phosphatase (ALP) of 669 U/L. A prostate biopsy revealed acinar adenocarcinoma with a Gleason score of 8 (4+4) and intraductal features. Immunohistochemical tests showed positive results for NKX3.1 and androgen receptor but negative results for PSA, synaptophysin, and chromogranin A. Given these findings, the patient was diagnosed with AVPC (cT3bN1M1b) and underwent androgen deprivation therapy combined with etoposide and cisplatin (EP) chemotherapy, achieving a partial response with marked improvements in his symptoms and lymph node lesions. Subsequent radium-223 therapy further reduced bone metastases and normalized ALP levels, leading to substantial functional recovery. This case underscores the necessity of maintaining a high index of suspicion for AVPC when clinical findings contradict low PSA values. Furthermore, the favorable response to EP highlights the potential role of platinum-based chemotherapy in managing low-PSA, high-grade PC. Additional cases are needed to refine the clinical characterization of AVPC and establish evidence-based treatment guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.